Summary The possibility of screening the general population for prostate cancer using serum prostate-specific antigen (PSA) level (alone or in combination with other tests) as screening test has recently been discussed. A number of studies are on the way, but the published reports have almost exclusively been based on men volunteering for screening. We assessed the feasibility of a screening study based on men identified from a central population registry. A random sample of 600 men in the age groups 55, 60 and 65 years was identified from the Finnish Population Registry as the study population. Half of them were randomised to the intervention group and an invitation to participate was sent to them. The participation rate was 77% (230 out of 300). Twenty-five men had a serum PSA concentration of 4.0 pg I-or above and were invited for further examination including digital rectal examination, transrectal ultrasound and transrectal Tru-cut biopsies (directed and/or random). Six cases of cancer were detected among the 230 participating men, which corresponds to a detection rate of 2.6% and a positive predictive value of 24%. The number of cases detected is equivalent to the expected number of prostate cancer cases during a 10 year follow-up in this population. The ratio of free to total PSA was also measured and a cut-off level of 0.20 was chosen. Its use as an additional criterion of the screening test would have decreased the prevalence of falsepositive screening tests from 8% (19 of 230) to 3% (7 of 230) at a cost of missing one of the six cancers compared with serum total PSA concentration alone. Of the six cancers, five were clinically regarded as localised and locally confined disease was confirmed pathologically in four of them. In conclusion, a population-based study in Finland seems feasible and the properties of the PSA test can be regarded as suitable for a randomised screening study. Thus, all prerequisites for a multicentre study, which is planned, seem to exist.
In recent years, the possibility of screening for prostatic carcinoma using measurement of serum prostate-specific antigen (PSA) concentration as the screening test has been subject to increasing interest.
The general prerequisites of screening for disease are: (1) the disease should have public health importance, i.e. it should be common and its health consequences significant; (2) the disease should have an early stage, during which it is detectable and the treatment results are more favourable compared with detection through normal clinical practice; (3) a screening test should be available with adequate sensitivity, specificity, as well as positive and negative predictive value; (4) the screening test should be acceptable to the target population and the cost and negative effects of the test should be in balance with the potential benefit from screening (modified from Wilson and Jungner, 1969) .
Prostate cancer is the second most common cancer among men in most industrialised countries with age-adjusted (to the world standard population) incidence rate approximately 50-100 per 100 000 person-years (Coleman et al., 1993) . The incidence rates are increasing 10-20% per five calendar years (Coleman et al., 1993) . Mortality varies between 10 and 20 per 100 000 person-years with little or no increasing trend (Coleman et al., 1993) . Thus, it clearly fulfils the first criterion of public health importance.
Radical treatment of early prostate cancer often leads to complete cure from the disease, which cannot be achieved in extracapsular disease (Walsh et al., 1994; Zagars et al., 1995) . Increased detection of organ-confined prostate cancer is possible by PSA-based screening (Catalona et al., 1993; Mettlin et al., 1993a) . Thus, the second criterion may also be fulfilled. This is on the condition that localised cancer implies early detection and that the favourable survival is not only due to lead time and lower aggressiveness of localised cancers. This potential fallacy can be assessed only by using mortality as the main endpoint.
Non-randomised studies of men volunteering for prevalence screening have shown sensitivity of 72% and specificity of 91% for the PSA test with a cut-off level of 4.0 pg 1-' (Labrie et al., 1992) . The corresponding positive predictive value has been 29-33% (Labrie et al., 1992; Brawer et al., 1993; Catalona et al., 1993; Mettlin et al., 1993b (Leinonen et al., 1996) .
Men with serum PSA concentration >4.0 pg 1' were referred to the Division of Urology, Tampere University Hospital. Urological examination of the screening-positive men was conducted, including a DRE and transrectal ultrasound (TRUS) of the prostate. TRUS was performed using a Briiel-Kjaer 1846 ultrasound scanner and a 7 MHz transducer (type 8551). Six random transrectal Tru-cut biopsies of the prostate were performed on all men with PSA>4.0 p,g 1-', supplemented by a directed biopsy if a suspicious focus was detected by DRE, TRUS or both.
Men in the control group were followed up for cancer incidence using a record linkage with the nationwide, population-based Finnish Cancer Registry, which has an almost complete coverage of cancer cases diagnosed in Finland (Teppo et al., 1994) .
Results
Of the 300 men invited, 230 participated (77%) ( Table I) All 25 men with PSA of 4.0 pg 1-1 or above were referred for urological examination. Among them, ten had a DRE finding indicative of cancer. A hypoechoic lesion was detected in TRUS for one of the 22 examined men (two men were not examined because of a broken machine). One of the men with elevated PSA went to a private urologist and no cancer was diagnosed, but information on DRE and TRUS findings are not available. Six cases of prostatic carcinoma were detected. This corresponds to positive predictive value of 24%. Other diagnoses were prostatic hyperplasia (n = 13), normal tissue (n = 2), metaplasia or atypical hyperplasia (n = 2), prostatitis (n = 1) and prostatic intraepithelial neoplasia (n = 1). Of the men with cancer, four had a PSA concentration between 4.0 and 10.0 pg I-', and two above 20 pg 1` ( Figure 1 ). Based on age-specific incidence rates in Finland, it was estimated that six prostate cancers corresponded to expected numbers of cases in a 10 year follow-up in the screened population.
Of the six cancers, four were grade I and two were grade II (Table II) . Five cancers were clinically confined to the prostate (one TI and four T2) and were treated by radical prostatectomy. Pathological staging confirmed organ-confined disease in four cases and revealed seminal vesicle invasion in one of the clinically localised tumours. The exact pathological stage for these cases were: Tlb, T2a, T2a, T2c, T3c. One case had both local invasion and bone metastases, (clinical stage T3 Nx Ml) and was treated with endocrine therapy (LHRH agonist). No pathological staging was available for this case.
All men with elevated PSA (4.0 pg 1-l or above), but without cancer diagnosis in the initial examination, were reexamined with DRE and biopsy at 1 year and those with PSA 10 pg 1-' also at 6 months from the initial examination. The follow-up has not revealed any additional prostate cancers.
The ratio of free to total PSA (F/T PSA) was also measured for all men. The relationship of the serum total PSA concentration and F/T PSA is shown in Figure (Stenman et al., 1990) .
The proportion of screening-positive men (11%) was similar to that observed in other studies (Chadwick et al., 1991; Brawer et al., 1992; Labrie et al., 1992; Catalona et al., 1993; Mettlin et al., 1993b (Carter et al., 1992; Helzlsouer et al., 1992; Paus et al., 1992; Stenman et al., 1994; Gann et al., 1995; Whittemore et al., 1995) . In these studies, no screening procedures were performed apart from drawing a blood sample for storage. Later on, the samples were analysed from subjects with subsequent prostate cancer and from controls. Thus, the advantage of these studies is the lack of overdiagnosis, i. Our results, although based on a small sample, support earlier results, suggesting that the combination of ratio of free to total PSA increases the specificity and the positive predicitive value of the screening test (Stenman et al., 1994) . The combination of the two tests, the total PSA and the ratio of free to total PSA, has the potential to substantially reduce the number of false-positive findings and hence the costs and harmful side-effects of a screening programme. However, the improved sensitivity can only be gained with some loss of specificity. In our study, one of the six cancers would have been missed if the screening positive finding was defined as serum PSA concentration of 4.0 ,ug 1ò r higher and F/T PSA 0.20 or below. We find this level of false negatives is acceptable, especially as overdiagnosis is one of the most important concerns for prostate cancer screening. Nevertheless, the usefulness of the F/T PSA will only be determined with further experience as our results need to be confirmed in larger studies. Also, more studies on the optimal cut-off level of the F/T PSA are needed.
Evaluation of the efficacy of a screening programme should be based on reduction of mortality from the disease, which can be done only on the basis of large randomised studies (Miller, 1982) . In prostate cancer, the potential reduction of prostate cancer mortality remains to be demonstrated with long-term follow-up and it may be small. Because of this and the facts that the treatment is associated with high frequency of side-effects and that the saved years of life are at an older age, assessment of quality of life is essential for evaluation of the possible benefit and harm caused by prostate cancer screening. Furthermore, the cost-effectiveness of the screening programme should be assessed. So far, no data are available regarding the effect of prostate cancer screening on mortality from the disease, nor on quality of life or cost-efficiency. A European collaborative study has been set up to investigate these end points, with Finland as a participating country (Schr6der et al., 1995) .
The results of our pilot study using a serum PSA cut-off level of 4.0 HIg I`suggest that a high participation rate can be achieved in the general population and that the proportion of screening-positive men, positive predictive value and detection rate are at an acceptable level. Thus, a population-based randomised study on screening for prostate cancer with prostate cancer mortality, quality of life and costefficiency as end points is feasible in Finland.
